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ABSTRACT
Malaria is a devastating disease caused by parasites of the genus Plasmodium.
Plasmodium falciparum, which is responsible for most malaria related fatalities,
suppresses host immune responses during heterologous coinfections or following
vaccination. However the mechanisms responsible for this defect are not well
defined. The mechanism and to what extent this immunosuppression is occurring
was investigated. This study demonstrates that both dendritic cell and T cell
activation are impaired following a Plasmodium infection, ultimately altering the
adaptive T cell response to secondary infections. T cell suppression is evident
early on following a secondary infection and continues throughout the peak of
parasitemia. To address the mechanism of Plasmodium T cell suppression of
heterologous infections, both T cell activation and expression of costimulatory
molecules on dendritic cells were analyzed. It was found that costimulatory
molecules on dendritic cells were downregulated, as well as the activation
markers CD25 and CD69 on CD8 T cells. These data demonstrate that
Plasmodium impairs T cell activation during heterologous infections. These data
provide insight into how Plasmodium may be altering immune responses to
coinfections in malaria endemic regions and how this could potentially change
the administration of vaccines that elicit CD8 T cell responses.
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Section I
Introduction

Malaria has been one of the deadliest infectious diseases throughout history and
continues to be a threat across the globe today. This disease can be extremely
debilitating, with symptoms including fever, chills, anemia, and even coma [1-4].
Throughout most tropical and subtropical regions the parasite responsible for this
disease, of the genus Plasmodium, continues to infect up to 500 million people
every year resulting in approximately one million deaths [2, 4]. The most
susceptible populations in these areas are young children under the age of five
and pregnant women [4]. Protection against this disease only arises following
repeated exposure to Plasmodium, and sterilizing immunity is never achieved [5,
6].
There are five species of Plasmodium that are capable of infecting
humans. Plasmodium ovale tends to be asymptomatic and results in a clinically
silent infection. Similarly, Plasmodium malariae also results in very few
symptoms or complications. Plasmodium vivax is the most common cause of
acute febrile illness and in some cases results in anemia, however this infection
is rarely lethal [4]. Plasmodium knowlesi is a zoonotic species that is specific to
1

macaques, but has been reported to infect humans in southeast Asia. The
deadliest by far of all Plasmodium species is Plasmodium falciparum [4]. The
blood stage of this disease oftentimes can result in death and has been shown to
display an ever increasing resistance to drug treatment [4]. Consequently, P.
falciparum is the target of extensive vaccine development and novel anti-malaria
drugs.
The life cycle of Plasmodium species is quite complex and is one of the
many tactics that this parasite employs to evade the immune system. Avoiding
the immune system and preventing clearance from the host enables the parasite
to establish infection and continue the spread of disease. The complex life cycle
of Plasmodium requires two hosts: a mosquito vector and a vertebrate host
(Figure 1). The transmission of Plasmodium species begins with development of
the parasite in the midgut of a female mosquito of the genus Anopheles. When
the mosquito takes a blood meal, it injects sporozoites with its saliva into the
dermis of the vertebrate host [7]. The sporozoites enter circulation and traverse
directly to the liver via an actinomysin motor, initiating the liver stage of disease
[1, 8]. During this stage, sporozoites rapidly invade hepatocytes and begin
differentiation and asexual replication [1]. The extent of the liver stage can last
anywhere from 10-12 days in humans and is clinically silent [1, 4, 9].
As the liver stage progresses, sporozoites develop into merozoites and
are released into the blood stream as merosomes, which are blebs of hepatocyte
membrane filled with merozoites [1]. Merosomes function as a “Trojan horse” to
2

Figure 1. Life cycle of Plasmodium parasite. Malaria: Evolution in vector control. Yannis
Michalakis & François Renaud. Nature 462, 298-300 (19 November 2009).
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carry the merozoites out of the liver where they eventually reach the lung and
rupture to release the merozoites [1]. Once in the blood stream, merozoites
infect red blood cells (RBCs) which results in the clinical disease, malaria [1, 4].
To infect a RBC, merozoites attach to a RBC and orient themselves into a
position to subsequently invade it [10]. Inside the parasitized red blood cell
(pRBC), the merozoite undergoes asexual reproduction, eventually rupturing the
RBC and releasing dozens more merozoites into the blood stream to infect more
RBCs [10]. This cycle of infectivity perpetuates the blood stage and can
ultimately lead to anemia and other hallmark signs of malaria [10].
During the maturation of the merozoites, the parasite will begin expressing
adherent ligands, such as P. falciparum erythrocyte membrane protein 1
(PfEMP1), which allows it to bind to multiple ligands on the vasculature, thus
preventing passage through the spleen [1, 10]. The spleen is a secondary
lymphoid organ that acts as a blood filter and removes pRBCs from the
bloodstream [11]. Consequently, expression of these adherent proteins provides
the parasite with another means of evading the host’s immune system and
continuing infection. Sequestration of pRBCs can also contribute to cerebral
malaria and complications during pregnancy, which occurs when pRBCs obstruct
blood vessels in the brain or placenta, respectively [1]. During the blood stage of
disease, merozoites may also differentiate into gametocytes, the sexually
reproductive form of the parasite. Gametocytes can be taken up by another
mosquito during a blood meal and undergo sexual reproduction. These forms of
4

the parasite will also differentiate again into sporozoites in the mosquito, allowing
their transmission into another vertebrate host (Figure 1) [1].
Although malaria vaccine development has made significant strides
toward a successful vaccination regimen, there still exists no licensed vaccine.
Plasmodium falciparum poses many problems when it comes to vaccine
development, including its polymorphic nature and antigenic variation [3, 12-16].
Vaccines have been targeted toward multiple stages throughout the parasite’s life
cycle including the pre-erythrocytic stage, the erythrocytic stage, and the sexually
reproductive stage [17-19]. In the past ten years, over 40 different vaccine
candidates targeting these various stages of disease have undergone clinical
trials [20]. However there has been limited success with the most advanced
candidate being the RTS,S/AS01 (RTS,S) vaccine [21]. This vaccine targets the
pre-erythrocytic stage, or the liver stage, of the parasite and is currently in a large
Phase III clinical trial in Africa. The RTS,S is comprised of pieces of the
circumsporozoite protein fused to the hepatitis B surface antigen (HBsAg) in the
adjuvant AS01 [17, 22]. The circumsporozoite protein is the major surface protein
found on the sporozoite that binds to liver heparan sulfate proteoglycans [1].
Unfortunately, the RTS,S provided only modest protection against malaria in
young infants 6 - 12 weeks of age, which is the intention-to-treat population [21].
The vaccine efficacy was only 30%, and the efficacy waned over time [21].
These discouraging results only further emphasize the need for an efficacious
malaria vaccine.
5

Other methods of malaria elimination and drug treatment are somewhat
effective although drug resistance has become increasingly recurrent. There are
several drugs available for malaria treatment, with one of the more common
being chloroquine. Because chloroquine-resistant strains of Plasmodium
falciparum have become a widespread problem, the most effective treatment
currently is artemisinin-based combination therapy (ACT). This involves a
combination of the drug artemisinin, or derivatives of artemisinin, and other
antimalarial drugs [23, 24]. By using combinations of antimalarial drugs, the
chance of the parasite developing drug resistance is much lower than using a
single drug. Vector control has also been implemented in many areas to control
transmission and to limit exposure to mosquitoes. Examples include using
insecticide-treated bed nets as well as residual indoor insecticide spraying [23].
Unfortunately, insecticide resistance is on the rise [23].
Although malaria is not a pandemic problem, it still occurs in practically all
tropical and subtropical regions. The Global Malaria Eradication Programme
(GMEP) was implemented in 1955 to prevent malaria transmission and ultimately
eradicate the disease [23, 25]. Seventy-nine countries eliminated malaria
between 1945 and 2010 [25]. However there has recently been a resurgence of
malaria transmission events, with 61 countries identifying new resurgent events.
These countries participated in the GMEP, but failed to reach complete
elimination [25]. Multiple programs such as this one have been put into action,
yet malaria transmission is still rampant across the globe and presents a major
6

threat to large populations, especially in sub-Saharan Africa. These data only
further support the need for malaria elimination and control.
In malaria endemic regions, there are multitudes of coinfections that can
occur with Plasmodium [26]. Malaria itself can be an extremely morbid and
devastating disease, however when infection occurs along with a secondary
infection, complications ensue within the host. Multiple studies have indicated
that when a Plasmodium infection occurs with a secondary infection, suppression
of the immune response to the secondary infection occurs [27-34]. It is during
the blood stage of infection when parasitemia is high that this
immunosuppressive activity occurs [26, 27, 29, 31-33].
This conundrum has been implicated with multiple types of infections,
including both bacterial and viral infections [34]. Plasmodium has been shown to
significantly increase susceptibility and mortality to multiple bacterial infections
including non-typhoid Salmonella, Streptococcus pneumoniae, Haemophilus
influenzae, Staphylococcus aureus, Acinetobacter species, E. coli, and
Pseudomonas aeruginosa [26, 31, 32]. The mechanisms behind this increase in
susceptibility has not been fully evaluated, although it was demonstrated that
Plasmodium impairs resistance to non-typhoid Salmonella by disrupting
neutrophil function [35].
Plasmodium species can impair immunity to viral infections as well [30,
32, 36-38]. Human immunodeficiency virus (HIV) is prominent throughout
practically all of sub-Saharan Africa. Individuals coinfected with Plasmodium and
7

HIV demonstrate higher viremia [26, 32, 39]. It has also been documented that
Epstein-Barr virus (EBV), when combined with a Plasmodium infection, can result
in endemic Burkitt’s lymphoma (eBL) [37]. Children coinfected with malaria and
EBV demonstrate higher viral loads and increased susceptibility to eBL [30, 36,
37]. Endemic Burkitt’s lymphoma is hypothesized to develop because of the loss
of T cell control of these EBV-infected B cells. Without the control of EBVinfected B cells, they are more likely to undergo abnormal proliferation and
subsequent transformation [30, 36].
Furthermore, immunity generated by vaccines is impaired by malaria.
Multiple vaccines including Salmonella typhi, tetanus toxoid, and meningococcal
polysaccharide exhibit reduced antibody responses when vaccinated individuals
are infected with Plasmodium [29, 33]. There is also diminished protection
against Plasmodium infection following vaccination with the malaria vaccine
candidate, RTS,S, in adults in malaria endemic regions compared to malaria
naïve adults [21]. Thus malaria is somehow impairing the immunity to vaccines
elicited to Plasmodium infected individuals, which further emphasizes the effects
this parasite may have on heterologous immune responses.
In addition to Plasmodium, other pathogens are also capable of
suppressing immune responses to coinfections. Of these, the most prominent is
HIV. HIV depletes the host of its CD4 T cells and eventually eliminates T cell
help [38]. There are several other pathogens that are immunosuppressive
including measles virus [40-42], helminth infections [43-47], viral hepatitis [488

50], and herpes simplex virus (HSV) [51, 52]. Measles virus induces a
lymphopenic environment, leading to a reduction in lymphocyte proliferation and
ultimately suppressing the immune response to subsequent pathogens [41, 42].
Although HIV and measles virus immunosuppression is better understood
mechanistically, the immunosuppressive characteristics of these other pathogens
are still unknown.
These data provide insight into a significant problem that has yet to be
fully addressed. There are rarely cases where an individual is infected with a
sole pathogen, especially in malaria endemic regions where coinfections are
quite common. Yet, there has been limited analysis in the ramifications that one
infection may impose on another. Malaria immunosuppression could potentially
have major implications on vaccines administered in malaria endemic areas.
Determining to what extent and by what mechanism this immunosuppression is
occurring will provide crucial information that could have a major affect on
vaccine delivery.
To examine Plasmodium-induced immunosuppression, two rodent-specific
species of Plasmodium (Plasmodium chabaudi and Plasmodium yoelii) were
employed to demonstrate immunosuppression with various heterologous (i.e.,
bacterial – Listeria monocytogenes and viral – lymphocytic choriomeningitis virus
(LCMV)) infections. Immunosuppression was observed following both bacterial
and viral coinfections. The mechanism by which this suppression occurs is
intrinsic to the activation of dendritic cells (DCs) and the priming and activation of
9

T cells. Collectively, these data provide detailed information into the
immunosuppressive capabilities of Plasmodium species and other infectious
pathogens, specifically LCMV. By examining immunosuppression in
Plasmodium specifically, it was determined that Plasmodium imparts a
deleterious effect on T cell activation resulting in suppression of the immune
response to subsequent infectious pathogens.

10

Section II
Materials and Methods

Mice and Infections
C57BL/6 mice were purchased from the National Cancer Institute (Frederick,
MD). Mice were housed at the University of Tennessee animal care facility under
the appropriate biosafety level. For Plasmodium infections, mice were infected
with either 105 Plasmodium yoelii 17XNL pRBCs or 106 Plasmodium chabaudi
chabaudi AS pRBCs. Mice that were infected with Plasmodium species were
infected at the indicated times with either 5 x 106 actA-deficient Listeria
monocytogenes-OVA (Lm-OVA) CFUs or 2 x 105 LCMV-armstrong PFUs. Mice
that were infected with wild type Listeria monocytogenes were infected with 1 x
104 Lm 10403s CFUs and infected at the indicated time with 2 x 105 LCMVarmstrong PFUs. Mice that were infected with LCMV followed by L.
monocytogenes were infected with 2 x 105 LCMV-armstrong PFUs or 2 x 106
LCMV-clone 13 PFUs followed by 5 x 106 actA-deficient Listeria monocytogenesOVA CFUs at the indicated times. LCMV-armstrong infections were performed
intraperitoneally. All other infections were done intravenously. The Institute
Animal Care and Use Committee approved all animal experiments.
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Quantification of Ag-specific T cells
Spleens and inguinal lymph nodes were disrupted to generate single-cell
suspensions in Hyclone RPMI media (Thermo Fisher Scientific Inc, Waltham,
MA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Inc.,
Lawrenceville, GA) and 3% supplementary complement. Supplementary
complement included HEPES (Thermo Fisher Scientific Inc, Waltham, MA), LGlutamine (Research Products International Corp., Mt. Prospect, IL), Pen/Strep
(Invitrogen, Grand Island, NY), Gentamicin Sulfate (Invitrogen, Grand Island,
NY), and 2-Mercaptoethanol (Thermo Fisher Scientific Inc, Waltham, MA). Livers
were perfused with cold PBS through the hepatic portal vein and made into single
cell suspensions using 35% Percoll/HBSS. Lungs were perfused through the left
ventricle with cold PBS and treated with DNase/collagenase for one hour prior to
generation of single-cell suspension. Single suspension cells were treated with
ammonium chloride potassium (ACK) to lyse red blood cells. Blood was
collected in heparinized collection natelson tubes and treated with ACK to obtain
peripheral blood mononuclear cells (PBMCs). Tissues were harvested as
indicated at the number of days post infection.
OVA-specific, LLO-190-specific, and LCMV-specific CD8 and CD4 T cells
were detected using intracellular cytokine staining (ICS) for IFN-γ. Cells were
incubated five hours with brefaldin A (Biolegend, San Diego, California) with or
without respective antigenic peptides (CD8 = 200 nM, CD4 = 4 μM) in Hyclone
12

RPMI media supplemented as described above. After incubation, cells were
stained with Fc block (anti-CD16/32; clone 2.4G2) and indicated antibodies (Abs)
resuspended in FACS buffer (1x PBS, 2% fetal calf serum, 0.02% sodium azide),
fixed and permeabilized with BD Cytofix/Cytoperm (BD Biosciences, San Diego,
California), stained for intracellular proteins, and washed with BD Perm/Wash
(BD Biosciences), San Diego, California). OVA-specific, NP396-specific, and
GP33-specific CD8 T cells were also detected by tetramer staining. Cells were
incubated with tetramers and Fc block in FACS buffer for 45 minutes. Antibodies
to cell surface markers were then added. Tetramers were generated from
biotinylated monomers (generously provided by John Harty, University of Iowa)
conjugated with streptavidin-APC (Invitrogen, Eugene, OR).

Antibodies
The following Abs were used from Biolegend (San Diego, California): CD8PerCP/Cy5.5, CD4-PerCP/Cy5.5, CD25-PE, CD69-FITC, CD40-PE, CD80-PE,
CD86 PE, Thy1.1-APC, and IFN-γ-FITC.

Parasitemia
Percent parasitemia was calculated by performing thin blood smears. Blood was
obtained by performing tail snips. Slides were fixed with methanol for ten
minutes and then stained using Giemsa stain (Thermo Fisher Scientific Inc,
Waltham, MA) diluted in PBS for 30 minutes.
13

BrdU assay
Mice were injected with 200 μL 10 mg/mL bromodeoxyuridine (BrdU) (SigmaAldrich, St. Louis, MO) solution intravenously three hours prior to spleen removal.
BrdU was put into solution with 1X sterile PBS. The BrdU Flow Kit (BD
Pharmingen, San Diego, California) was used for labeling BrdU+ cells. Singlecell suspensions were generated and cells were stained with specific fluorescent
Abs. Cells were then fixed with BD Cytofix/Cytoperm, washed with BD
Perm/Wash, and incubated with BD Cytoperm Permeabilization Buffer Plus.
Cells were then treated with DNase and incubated for one hour. The cells were
then stained for BrdU with fluorescent α-BrdU antibodies and incubated for 20
minutes at room temperature. BrdU+ cells were analyzed using flow cytometry.

Caspase 3/7 assay
Spleens were disrupted into single-cell suspension. The Caspase-3 and -7
Assay Kit (Invitrogen, Grand Island, NY) was used to detect apoptosis. A 30X
FLICA working solution was added to cells and incubated for 1 hour at 37°C and
5% CO2. Cells were washed with 1X wash buffer and stained with a tetramer
followed by cell surface fluorescent antibodies. Detection of caspase-3 and -7
was detected using flow cytometry.
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Adoptive transfer of OT-I TCR Transgenic CD8 T cells
Thy 1.1+ transgenic mice were used as sources of OT-I’s. Spleens and lymph
nodes were removed and disrupted into a single-cell suspension. OT-I’s were
isolated using a CD8α+ T cell isolation kit II (Miltenyi Biotec, Cologne, Germany).
OT-I transgenic T cells were quantified and injected intravenously at the indicated
amount.

Statistical analysis
All statistical analyses were performed using the Prism 6.0c software. Significant
data were represented by the following: * p=0.05-0.01, ** p=0.01-0.001,
*** p=0.001-0.0001, ****p<0.0001
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Section III
Results

Plasmodium yoelii 17XNL suppresses T cell responses to a bacterial
coinfection
Previous studies have indicated that Plasmodium falciparum impairs resistance
and increases susceptibility to multiple diseases, including both bacterial and
viral infections [26, 27, 31, 32, 37, 38]. In one particular study, it has been
demonstrated that P. falciparum causes neutrophil dysfunction during nontyphoid Salmonella coinfections [35]. This bacterial infection is most commonly
associated with malaria in several regions throughout sub-Saharan Africa [31,
32]. Therefore the objective was to determine to what extent adaptive immunity
to heterologous coinfections was affected following a Plasmodium infection. The
non-lethal strain of Plasmodium yoelii (P. yoelii 17XNL) was employed to serve
as the Plasmodium model due to it causing an acute infection with high
parasitemia. C57BL/6 mice were infected with 105 P. yoelii parasitized red blood
cells (pRBCs) at day 0. Seven days following the P. yoelii infection, both naive
and P. yoelii infected mice were infected with 5 x 106 actA-deficient Listeria
monocytogenes CFUs specifically expressing the protein, ovalbumin (Lm-OVA).
The Lm-OVA strain was an attenuated strain deficient in the actA protein,
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preventing the bacteria from spreading from cell to cell [53]. Using this strain
provided a means to monitor OVA-specific CD8 T cells that responded to the LmOVA infection. Parasitemia of this P. yoelii strain was also monitored in order to
determine the magnitude of infection (Figure 2). Parasitemia was found to peak
at approximately day 18 post-Plasmodium infection.
A reduction in OVA-specific CD8 T cells was evident the first two weeks
following Lm-OVA infection (Figure 3A,B). CD4 T cells specific for the LLO-190
peptide were also suppressed following the Lm-OVA infection, although only
significantly through day 14 (Figure 3C,D). These data provided insight into how
extensive immunosuppression was occurring, with CD8 T cells being significantly
depleted through day 21 of the experiment (Figure 3B). Although CD4 T cells
were not suppressed to the degree that CD8 T cells were (7-fold and 11-fold,
respectively), there was still a significant (p = 0.0001) reduction in their numbers
at day 14 (Figure 3D). Both CD8 and CD4 T cell numbers recovered by day 35,
indicating that these immunosuppressive events occur early following the P.
yoelii infection. The timing of T cell recovery corresponded with parasite
clearance, indicating that the presence of the parasite was playing a role in T cell
suppression.

17

Figure 2. Percent parasitemia following P. yoelii infection. C57BL/6 mice were
5
infected with 10 P. yoelii 17XNL (Py) pRBC. Blood smears were taken starting at day
7 and continued throughout infection. Percent parasitemia was calculated by Giemsa
staining blood smears and performing parasitized red blood cell counts.
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Figure 3. P. yoelii 17XNL induces short-term suppression of T cell responses to
5
secondary L. monocytogenes infection. C57BL/6 mice were infected with 10 P. yoelii
17XNL (Py) pRBC. At various times post Py infection both naïve and Py infected mice
6
were infected with 5x10 actA-deficient L. monocytogenes expressing ovalbumin (Lm).
Lm-specific T cells were analyzed one-week post Lm infection. Representative contour
plots showing percent of CD8 T cells (A) or CD4 T cells (C) that are IFN-γ positive
following stimulation with indicated peptide and intracellular cytokine stain (ICS). Number
of OVA-specific CD8 T cells (B) and LLO190-specific CD4 T cells (D) per spleen were
quantified at the indicated time points. Data (mean+S.E.M.) are cumulative results from at
least three independent experiments. LLO190-specific CD4 T cell numbers at day 21, 35,
and 70 are from one experiment. Data were analyzed by Student’s unpaired two-tailed t
test.
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P. chabaudi induces suppression of T cells responding to secondary LmOVA infection
There are multiple species and strains of Plasmodium that cause malaria.
Therefore, it is important to understand to what degree other Plasmodium
species suppress T cell responses to coinfections. Plasmodium chabaudi AS is a
widely used murine Plasmodium model because it induces a chronic infection,
which is similar to infection with P. falciparum infection in humans [54]. However
peak parasitemia is lower than that observed in P. yoelii. This provided another
means to examine variable levels of parasitemia and how parasite loads could
potentially impact the T cell response to coinfections.
To determine whether P. chabaudi also impaired T cell responses to a
bacterial coinfection, C57BL/6 mice were infected with 106 P. chabaudi AS
pRBCs on day 0. On day 7, naïve and P. chabaudi infected mice were
subsequently infected with 5 x 106 actA-deficient Lm-OVA CFUs. Similar to P.
yoelii, P. chabaudi infected mice exhibited reduced OVA-specific CD8 T cells and
LLO-specific CD4 T cells on day 14, however this was the only time point that
showed significant differences (Figure 4). Although there was a significant
decrease in T cell numbers (p=0.0040), the decrease in OVA-specific CD8 T
cells was not as severe as the P. yoelii infection (Figure 4A). This could
potentially be due to P. chabaudi causing a lower level of parasitemia (data not
shown) compared to that of P. yoelii. By day 21, T cell numbers were still lower
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Figure 4. Suppression of T cells responding to secondary L. monocytogenes infection is
6
observed in P. chabaudi AS infected mice. C57BL/6 mice were infected with 10 P. chabaudi
AS (Pc) pRBC. At various times post Pc infection both naïve and Pc infected mice were infected
6
with 5x10 actA-deficient Lm. Lm-specific T cells were analyzed one-week post Lm infection. OVAspecific CD8 T cells (A) or LLO190-specific CD4 T cells (B) were determined by ICS for IFN-γ.
Data (mean+S.D.) are from three mice per group. Data were analyzed by Student’s unpaired twotailed t test.
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in P. chabaudi infected mice, although neither OVA-specific CD8 nor LLOspecific CD4 T cell numbers were significantly reduced (Figure 4). As
demonstrated previously with P. yoelii, T cell numbers returned to normal by day
35 following the P. chabaudi infection. By examining both of these murine
Plasmodium species, suppression of T cell responses to secondary bacterial
infections was demonstrated to occur with various species and strains. Thus,
Plasmodium species were capable of imparting immunosuppressive effects on T
cell responses to secondary infections in the first two weeks following a
Plasmodium infection.

Immunosuppression of T cell response to viral infection occurs following a
P. yoelii infection
While there are many bacterial infections that could accompany a Plasmodium
infection in malaria endemic areas, there are also reports of individuals displaying
a higher susceptibility to viral infections, including HIV and EBV, when infected
with malaria [30, 36-38]. Thus, it was also necessary to determine whether
suppression of the immune response to a viral infection could occur. For this
experiment, lymphocytic choriomeningitis virus (LCMV) was utilized to serve as a
viral infection. LCMV-armstrong strain induces an acute infection and is typically
cleared from the murine host within 8 days. On day 0, C57BL/6 mice were
infected with P. yoelii and one week later, naive and P. yoelii infected mice were
infected with 2 x 105 LCMV-armstrong PFUs. Eight days after the LCMV22

armstrong infection (day 15), LCMV-specific T cells were analyzed. The major
antigenic peptides are NP396, GP33, and GP276 for CD8 T cells and GP61 for
CD4 T cells. For all three CD8 T cell responses analyzed, there was a significant
reduction in numbers (Figure 5A,B). Similarly, GP61-specific CD4 T cells were
lower in P. yoelii infected mice (Figure 5C,D). These data demonstrate that P.
yoelii also suppresses T cell responses to viral coinfections.

Immunosuppression is not attributed solely to Plasmodium species
After demonstrating that Plasmodium could suppress the adaptive immune
response to coinfections, it was hypothesized that other types of infection could
exhibit immunosuppression of coinfections as well. Chronic viral infections can
display immunosuppressive activity and induce functional impairment and
suppression of virus-specific CD8 T cells, specifically in LCMV-clone 13 [55].
During persistent viral infections, immunosuppressive effects can be observed
with altered immunodominance profiles and tissue distribution, ultimately altering
the viral T cell response to infections [55]. Therefore, the objective was to
determine whether immunosuppression of coinfections was attributed solely to
Plasmodium, or whether this could occur with other infections as well. To test
this, LCMV was used to serve as the viral infection. LCMV-armstrong strain and
LCMV-clone 13 strain cause an acute and chronic infection, respectively. These
two strains provided a means to observe differences in immunosuppression with
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Figure 5. P. yoelii 17XNL suppresses T cell responses to a viral coinfection.
5
C57BL/6 mice were infected with 10 P. yoelii 17XNL (Py) pRBC. One-week after Py
5
infection naïve and Py infected mice were infected with 2x10 lymphocytic
choriomeningitis virus (LCMV) Armstrong. LCMV-specific T cells were analyzed 8
days post LCMV infection. Representative contour plots showing percent of CD8 T
cells (A) or CD4 T cells (C) that are IFN-γ positive following stimulation with indicated
peptide and ICS. Number of NP396-, GP33- and GP276-specific CD8 T cells (B) and
GP61-specific CD4 T cells (D) per spleen. Data (mean+S.E.M.) are cumulative
results from two independent experiments. Data were analyzed by Student’s
unpaired two-tailed t test.
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both an acute and chronic strain, as was seen with the Plasmodium strains
(Figures 3, 4, and 5).
C57BL/6 mice were infected with either 2 x 105 LCMV-armstrong PFUs or
2 x 106 LCMV-clone 13 PFUs on day 0. One week later, naïve and LCMV
infected mice were infected with 5 x 106 actA-deficient Lm-OVA CFUs. It was
determined that both strains were capable of inducing immunosuppression
(Figure 6). Both LCMV-armstrong and LCMV-clone 13 demonstrated a
substantial reduction in the Lm-OVA CD8 and CD4 T cell responses at day 14.
Several mice in both LCMV-armstrong and LCMV-clone 13 infected groups had T
cell responses below the limit of detection at day 14, therefore statistical analyses
were not performed on these data for this time point (Figure 6B,D). LCMV-clone
13 demonstrated a much more severe suppressive capacity throughout the entire
experiment for both CD8 and CD4 T cells. OVA-specific T cell responses in
these mice were significantly suppressed through day 70, indicating a long-term
suppressive effect elicited by this virus. LCMV-armstrong suppressed the
Listeria T cell response through day 21, but the response returned to normal by
day 35 (Figure 6B,D). These differences in immunosuppressive capabilities
could be due to multiple factors that have yet to be examined. Because LCMVclone 13 causes a much more systemic and chronic infection, it was expected
that this strain would cause more T cell suppression. These data demonstrate
that Plasmodium was not the only pathogen capable of suppressing immune
responses to secondary infections, but a viral infection could as well.
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Figure 6. Acute and chronic viral infections suppress T cell responses to secondary L.
5
monocytogenes infection. C57BL/6 mice were infected with either 2x10 LCMV Armstrong (Arm)
6
or 2x10 LCMV clone 13 (cl 13). At various times post LCMV infection naïve and LCMV infected
6
mice were infected with 5x10 actA-deficient Lm-OVA CFUs. Lm-specific T cells were analyzed
one-week post Lm infection. Number of OVA-specific CD8 T cells (A) and LLO190-specific CD4 T
cells (B) per spleen at the indicated time points were determined by ICS for IFN-γ. LOD = limit of
detection. Data (mean+S.E.M.) are cumulative from 2 separate experiments. Data for CD8 T cells
on days 35 and 70 were analyzed by one-way ANOVA followed by Tukey’s multiple comparison
test. Data for CD8 T cells on day 21 and data for CD4 T cells on days 21, 35, and 70 were
analyzed by a Kruskal-Wallis test followed by Dunn’s multiple comparison test.

26

Wild type Listeria infection has little to no effect on the immune response
to viral coinfection
After demonstrating that a viral infection was capable of suppressing a bacterial
immune response, immunosuppression by other types of pathogens was further
investigated by examining whether a bacterial infection was able to alter the T
cell response to a viral infection. To test this, a wild type strain of Listeria
monocytogenes (Lm 10403s) served as a bacterial infection. This strain is more
pathogenic than the strain used in previous experiments, as it is not deficient in
the actA protein. C57BL/6 mice were infected with 104 Lm 10403s CFUs on day
0 and subsequently infected with LCMV-armstrong on days 7 and 14. On days
15 and 22, NP396-, GP33-, and GP276-specific CD8 and GP61-specific CD4 T
cell responses were analyzed. At days 15 and 22, CD8 T cell responses were
not altered in mice (Figure 7C,E). It was shown that, on day 15, CD4 T cell
responses were slightly less than that of LCMV only infected, but there was no
difference by day 22 (Figure 7D,F). Thus, a virulent Listeria infection had little
impact on T cell responses to a viral coinfection. Therefore, suppression of T cell
responses to coinfections is not a universal observation for all pathogens.
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Figure 7. Virulent L. monocytogenes infection exhibits little to no impact
on T cell responses to secondary LCMV infection. C57BL/6 mice were
4
infected with 0.5-1x10 virulent L. monocytogenes (strain 10403s) (Lm). At
various times post Lm infection naïve and Lm infected mice were infected with
5
2x10 LCMV Armstrong. LCMV-specific T cells were analyzed 8 days post
LCMV infection. Number of NP396-, GP33- and GP276-specific CD8 T cells (A)
and GP61-specific CD4 T cells (B) per spleen were determined by ICS for IFN-γ
at the indicated time point. Data (mean+S.E.M.) are cumulative results from two
independent experiments. Data were analyzed by Student’s unpaired two-tailed t
test.
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P. yoelii infection results in a loss of Listeria-specific CD8 T cells in
multiple tissues
In order to examine the mechanism of immunosuppression, it was important to
determine if there was a loss of coinfection-specific T cells in other tissues
besides the spleen. It was critical to ensure that T cells being presented antigen
in the spleen were not migrating to other tissues upon activation, thus
contributing to the loss of T cell numbers in the spleen that was seen in previous
experiments. To address this possibility, C57BL/6 mice were infected with 105 P.
yoelii 17XNL pRBCs on day 0. On day 7, naive and P. yoelii infected mice were
infected with 5 x 106 actA-deficient Lm-OVA CFUs. One week later, the spleen,
inguinal lymph nodes (iLN), liver, lungs, and blood were collected and OVAspecific CD8 T cells were quantified using tetramer staining. There was a
significant loss of T cell numbers in multiple tissues throughout the body, which
demonstrated that T cell migration to tissues outside the spleen was not
contributing to the impaired response (Figure 8). These data demonstrated that
depletion of the OVA-specific CD8 T cell response was accurately detected in the
spleen and that migration of the T cells was not contributing to a loss in numbers
in the spleen (Figure 8). This suggests that a loss of OVA-specific CD8 T cells in
the spleen was not being compensated by an increase in other tissues and that a
reduction in the T cell response was occurring throughout the body. Therefore, P.
yoelii induces systemic suppression of Listeria-specific T cells during a
coinfection.
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Figure 8. Loss of Listeria-specific CD8 T cells during Plasmodium infection
5
occurs in multiple tissues. C57BL/6 mice were infected with 10 P. yoelii 17XNL
(Py) pRBCs at day 0. One week later, naïve and Py infected mice were infected
6
with 5x10 actA-deficient Lm-OVA. Spleens, livers, inguinal lymph nodes (iLN),
lungs, and blood were taken from mice and analyzed 14 days post Lm infection.
OVA-specific CD8 T cells were quantified using tetramer staining. Data
(mean+S.E.M.) are cumulative from two independent experiments. Data were
analyzed using Student’s unpaired two-tailed t test.
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Defect in T cell response occurs early after Lm-OVA infection
One explanation for the observed decrease in Listeria-specific T cells in
Plasmodium infected mice is altered kinetics of the T cell response. To address
this possibility Listeria-specific CD8 T cell responses were quantified at multiple
time points. C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs on day
0 and infected with 5 x 106 actA-deficient Lm-OVA CFUs one week later. OVAspecific CD8 T cells were quantified daily day 4 through day 10 post Lm-OVA
infection. Suppression of OVA-specific CD8 T cells occurred as early as day 4
following the Lm-OVA infection and lasted through day 7 (Figure 9). The early
decrease in OVA-specific CD8 T cells in P. yoelii infected mice suggests there is
a defect in the early stages of T cell priming that causes the decrease of Listeriaspecific T cells in P. yoelii infected mice.

Loss of CD8 T cells is not due to decrease in proliferation
The decrease in Listeria-specific T cells in P. yoelii infected mice is likely
attributed to either a decrease in proliferation or increased apoptosis. To examine
the proliferative potential of OVA-specific CD8 T cells in P. yoelii + Lm-OVA
infected mice, C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs on
day 0 and one week later infected with 5 x 106 actA-deficient Lm-OVA CFUs.
Beginning at day 4 post-Lm-OVA infection and continuing through day 9, mice
were injected with 10 mg/mL bromodeoxyuridine (BrdU). BrdU is a thymidine
analog that is incorporated into the DNA of dividing cells and can be
31

Figure 9. Suppression of T cells occurs early following Listeria infection.
5
C57BL/6 mice were infected with 10 P. yoelii 17XNL pRBCs at day 0. On day 7,
6
naïve mice and Py infected mice were infected with 5x10 actA-deficient LmOVA. (A) OVA-specific CD8 T cells were detected starting at day 4 post Lm
infection. OVA-specific CD8 T cells were quantified using tetramer staining.
Data (Mean+S.E.M.) are cumulative results from four separate experiments.
Data were analyzed by Student’s unpaired two-tailed t test.
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tracked with BrdU-specific antibodies. Three hours after injection of BrdU,
spleens were removed for analysis of BrdU incorporation in OVA-specific CD8 T
cells. The data indicated there was no significant difference in proliferation in
OVA-specific CD8 T cells early in the response (days 4 and 5) (Figure 10).
Surprisingly, OVA-specific CD8 T cells in P. yoelii + Lm-OVA infected mice
exhibited higher rates of BrdU incorporation on days 6 through 8 (Figure 10).
These results demonstrate that P. yoelii does not impair Listeria-specific CD8 T
cells through decreased proliferation. This observation could help explain why
there is a delay in the peak OVA-specific CD8 T cell response in P. yoelii infected
mice as demonstrated in Figure 9.

An increase in apoptosis occurs in OVA-specific CD8 T cells during a P.
yoelii plus Lm-OVA infection
Since there was no reduction in proliferation, this suggested differences in
apoptosis might contribute to decreased T cell responses in P. yoelii infected
mice. To determine if OVA-specific T cells exhibited different rates of apoptosis,
a caspase-3/7 assay was used to monitor apoptotic cells. This assay measures
the activity of caspases-3 and -7, two proteins that are proteolytically cleaved and
activated during apoptotic signaling events [56]. By measuring the activation
levels of these two proteins, apoptotic cells can be enumerated via flow
cytometry. C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs at day 0
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Figure 10. Suppression of CD8 T cell response is not due to a decrease in
5
proliferation. C57Bl/6 mice were infected with 10 P. yoelii 17XNL pRBCs at day 0. On
6
day 7, naïve mice and Py infected mice were infected with 5x10 actA-deficient Lm-OVA.
At days 4 – 10 post Lm infection, mice were injected with BrdU 3 hours prior to spleen
removal to determine proliferation of OVA-specific CD8 T cells. Data (mean+S.E.M.) are
cumulative results from four separate experiments. Data were analyzed by Student’s
unpaired two-tailed t test.
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and one week later infected with 5 x 106 actA-deficient Lm-OVA CFUs. Starting
at day 11, apoptosis was monitored through day 15 for detection of active
caspase-3/7+ cells.
There were significant differences in apoptosis six and seven days postListeria infection in P. yoelii plus Lm-OVA infected mice (Figure 11). On day 11,
OVA-specific CD8 T cells in P. yoelii infected mice were undetectable. By day 12
there were enough cells to be able to detect caspase 3/7+ cells, although
apoptosis only proved to be significantly higher starting at day 13 (Figure 11).
Both days 13 and 14 were significant (p=0.0041, p=0.0002 respectively) and
demonstrated that P. yoelii infected mice had higher levels of OVA-specific
apoptotic cells. By day 15, there were no differences in apoptosis. From these
data, it can be concluded that apoptosis may be contributing to a reduction in the
OVA-specific T cell response following a P. yoelii infection.

OT-I TCR Tg T cells behave similarly to endogenous CD8 T cell response
Collectively, the data suggest alterations in antigen presentation and T cell
priming likely contribute to decreased T cell responses and increased
susceptibility to apoptosis. To address these mechanisms requires the analysis
of T cells early after T cell priming, which can only be accomplished through
adoptive transfer of large numbers of T cell receptor transgenic (TCR-Tg) T cells
specific for ovalbumin (OT-I TCR Tg T cells). Prior to utilizing OT-I TCR Tg T
cells, it was important to demonstrate that they behaved similar to the
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Figure 11. Apoptosis contributes to loss of CD8 T cell response. C57BL/6 mice
5
were infected with 10 P. yoelii 17XNL pRBCs at day 0. On day 7, naïve mice and Py
6
infected mice were infected with 5x10 actA-deficient Lm-OVA. At days 4 – 8 post Lm
infection, OVA-specific CD8 T cells were stained for Caspase 3/7 to determine
apoptotic cell numbers. Data (mean+S.E.M.) are cumulative results from two separate
experiments. Data were analyzed by Student’s unpaired two-tailed t test. n.d. = not
detectable.
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endogenous response in P. yoelii + Lm-OVA infected mice. C57BL/6 mice were
injected with 250 OT-I TCR Tg T cells that were adoptively transferred from a
Thy1.1+ transgenic mouse into Thy1.2+ C57BL/6 mice. A low number adoptive
transfer was performed in order to mimic the endogenous naïve T cell pool.
Twenty-four hours later, mice were infected with 105 P. yoelii 17XNL pRBCs, and
one week later, naïve and P. yoelii mice were infected with 5 x 106 actA-deficient
Lm-OVA CFUs. Starting at day 12, OT-I TCR Tg T cells were quantified over a
five day span.
Importantly, the kinetics of the OT-I TCR Tg T cell response (Figure 12)
were comparable to the endogenous response (Figure 9). Suppression of the Tg
T cell response was detected as early as day 12, although T cell numbers were
not analyzed prior to this time point. However, P. yoelii plus Lm-OVA infected
mice displayed similar kinetics of the T cell response to that of the endogenous
response (Figure 9). The peak of the P. yoelii response was delayed by 24
hours. These results demonstrate that OT-I TCR Tg T cells followed similar
kinetics as seen in the endogenous response of P. yoelii + Lm-OVA infected
mice. Consequently, OT-I TCR Tg T cells provide a sufficient model for
monitoring T cell priming and activation following a Lm-OVA infection.
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Figure 12. Adoptively transferred OT-I’s behave similarly to the endogenous
CD8 T cell response. Two hundred fifty OT-I’s were adoptively transferred into naïve
5
C57BL/6 mice. Half of these mice were infected with 10 P. yoelii 17XNL pRBCs one
6
day later (day 0). At day 7, naïve and Py infected mice were infected with 5x10 actAdeficient Lm-OVA. At days 12 – 17, OT-I cell numbers were quantified by cell surface
staining. Data (mean+S.E.M.) are cumulative results from two separate experiments.
Data was analyzed by Student’s unpaired two-tailed t test.
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Plasmodium causes impaired activation of coinfection-specific T cells
Due to immunosuppression being observed early following a Listeria infection, it
was imperative to investigate whether initial priming of T cells was affected in
some way by a Plasmodium infection. Following both TCR stimulation and
costimulation, the cell surface markers CD69 and CD25 are upregulated and
serve as an indicator for T cell activation [57-59]. Therefore, induction of CD69
and CD25 were examined to determine whether P. yoelii impaired T cell
activation events following Lm-OVA infection. To examine these two activation
markers, C57BL/6 mice (Thy1.2+) received ~2 x 106 adoptively transferred OT-I
TCR Tg T cells from a Thy1.1+ TCR Tg mouse at day 0. Mice were then infected
with 105 P. yoelii 17XNL pRBCs later on the same day. One week later naive
and P. yoelii infected mice were infected with 5 x 106 actA-deficient Lm-OVA
CFUs. Expression of CD25 and CD69 was analyzed on days 1, 2, and 3 post
Lm-OVA infection. Mean fluorescence intensity was quantified to determine the
level of expression for both CD25 (Figure 13C) and CD69 (Figure 13D). CD25
expression was reduced in the P. yoelii infections for three days following the LmOVA infection (Figure 13C). Similarly, the percentage of CD25+ OT-I T cells was
also significantly lower in P. yoelii infected mice three days following Lm-OVA
infection (Figure 13E).
CD69 mean fluorescence intensity was significantly (p=0.0095) impaired
one day following the Lm-OVA infection but expression in both groups of mice
was reduced the following two days (Figure 13D). The percentage of CD69+ OT-I
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Figure 13. Activation markers are downregulated on T cells. At day 0, 1.5 – 1.8 x
6
10 OT-I’s were adoptively transferred into naïve C57BL/6 mice. Mice were infected
5
6
with 10 P. yoelii 17XNL pRBC and one week later infected with 5x10 actA-deficient
Lm-OVA CFUs. On days 8, 9, and 10, OT-I cells were stained for CD25 and CD69.
Histograms for CD25 (A) and CD69 (B) were quantified to determine CD25+ and
CD60+ OT-I T cells. Mean fluorescence intensity of CD25 (C) and CD69 (D) in OT-I T
cells was quantified using flow cytometry. Percentage of CD25+ (E) and CD69+ (F)
OT-I T cells was also determined by fluorescent staining and flow cytometry. Total cell
numbers of Tg OT-I T cells were quantified by cell surface staining for Thy 1.1 (G).
Data is representative of two separate experiments. Data were analyzed by Student’s
unpaired two-tailed t test.
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T cells on day 8 was lower in P. yoelii infected mice, although this time point did
not prove to be significant (Figure 13F). At day 9, there were similar numbers of
CD69+ OT-I T cells which was synonymous with reduced MFI in both groups of
mice at the same time point (Figure 13D,F). By day 10, the MFI and percentage
of CD69+ OT-I T cells were both extremely low and there were no differences
between the groups (Figure 13D,F). From these data it can be concluded that T
cell activation is impaired following TCR engagement as shown by the reduction
in activation markers.

Costimulatory molecules on dendritic cells in P. yoelii infected mice are not
upregulated following Listeria infection
There have been contradictory studies thus far on how Plasmodium species
affect dendritic cell function and whether altered antigen presentation could be
playing a role in suppression of T cell responses [60]. While reports have
demonstrated that DCs are affected by malaria infection in the field [61, 62], there
are inconsistent results from mouse models of malaria [63-69]. To address how
dendritic cells were being affected by a P. yoelii infection, activation of dendritic
cells was observed by investigating the level of expression of three costimulatory
molecules: CD40, CD80, and CD86. Full activation of T cells is dependent on
these costimulatory molecules [70], thus this provided a means to look at DC
function.
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C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs on day 0.
One week later, both naïve and half of the P. yoelii infected mice were infected
with 5 x 106 actA-deficient Lm-OVA CFUs. At 24 hours post-Lm infection, DCs
were monitored for expression of costimulatory markers.
All three molecules were downregulated following Lm-OVA infection, with
CD86 being the most significantly impaired. CD86 exhibited the greatest
decrease in expression in P. yoelii only infected mice and P. yoelii plus Lm-OVA
infected mice (Figure 14A). CD40 and CD80 expression were significantly
impaired as well, though not to the extent of CD86 (Figure 14B). These data
suggest that Plasmodium is capable of compromising the activation of dendritic
cells by reducing the expression of costimulatory molecules on the DC’s surface,
thus inhibiting T cell activation as well.
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Figure 14. Costimulatory molecules are downregulated on dendritic cells.
5
Mice were infected with 10 P. yoelii 17XNL pRBC on day 0 and one week later
6
infected with 5x10 actA-deficient Lm-OVA CFUs. On day 8, dendritic cells were
stained with CD40, CD80, and CD86 (A) and mean fluorescence intensity (MFI)
was quantified for each costimulatory molecule (B). Data is representative of two
cumulative experiments. Data were analyzed by one-way ANOVA followed by
Tukey’s multiple comparison test.
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Section IV
Conclusion
The host’s immunity to disease has mainly been studied in the context of tracking
the immune response to a single infectious pathogen. However individuals are
often infected by more than one pathogen. While there have been reports
documenting suppression of immune responses following coinfections [27, 32-34,
38, 39, 41, 50, 51, 71-73], the mechanisms and extent to which
immunosuppression occurs remains unknown for most pathogens. This lack of
information presents a critical knowledge gap that needs to be addressed,
especially in malaria endemic regions where coinfections are extremely
prominent. Evaluating immunosuppression and its effects will provide much
needed information for disease treatment and vaccine delivery in these malaria
endemic regions.
To address this problem, an experimental system was devised to examine
immunosuppression in heterologous coinfections. By utilizing multiple pathogens
(e.g., Plasmodium, LCMV, and Listeria) the extent of immunosuppression was
evaluated in multiple coinfections. The results generated from these experiments
demonstrate that immunosuppression is most severe in P. yoelii and LCMV-clone
13 infections. This could potentially be due to the magnitude and/or duration of
infection with these two pathogens. The data demonstrated that their
suppressive effects were greater than that of P. chabaudi and LCMV-armstrong,
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which were short-lived infections. For example, although P. chabaudi exhibited
immunosuppression early after infection, it did not occur to the degree of P.
yoelii. P. chabaudi generates a chronic infection but with much lower levels of
parasitemia. Parasitemia levels in the P. chabaudi only reached 7% (data not
shown), while P. yoelii reached up to 50% pRBCs. Likewise LCMV-armstrong
did not display the same magnitude of immunosuppression as did LCMV-clone
13. LCMV-armstrong results in an acute infection that is cleared from the host
within eight days [55]. On the contrary LCMV-clone 13 causes a chronic infection
that can result in viremia that persist in some tissues indefinitely, which could
perpetuate immunosuppression as shown in these data [55].
Whereas P. yoelii and LCMV-clone 13 demonstrated greater levels of
immunosuppression, it appeared that wild type L. monocytogenes was not
immunosuppressive (Figure 7). Although this virulent strain was lethal to onethird of the mice infected (data not shown), immunosuppression did not occur.
These data suggest that not all infections suppress T cells responding to
heterologous infections, however it is not known what dictates the differential
outcome. Importantly, the model system employed here will allow for
mechanistic studies to determine why some infections impair T cell responses to
subsequent infections while others do not.
These data may also provide information for the treatment of coinfections
in Plasmodium-infected individuals. Disease treatment and vaccine
administration in Plasmodium-infected individuals comes into question if
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immunosuppression alters the immune response to an infection. Furthermore, if
the immune system is incapable of mounting an appropriate response, then
administering a vaccine could be dramatically impaired. Indeed, there has been
much debate on whether individuals infected with malaria should be given a
vaccine if they are already present in the clinic [32, 34, 74]. A major problem in
developing countries is getting people into the clinic to actually receive vaccines,
therefore some suggest if individuals are already in the clinic then they should be
vaccinated regardless of whether they have malaria or not [75]. This is especially
relevant in vaccination regimens that require multiple boosters over the course of
several months or years. However, it is unknown if there is a correlation between
parasite burden and impaired host immunity in humans. Thus determining the
mechanism and extent of immunosuppression in humans could provide valuable
information that would determine when a vaccine should be administered to
someone with malaria.
Previous studies have indicated that P. falciparum alters the adaptive
immune response, increases susceptibility to heterologous infections, and
modulates dendritic cell function [26, 28-33, 37, 39, 44, 48, 63]. However, there
are conflicting reports about the mechanism behind immunosuppression, which
have primarily focused on dendritic cells using malaria mouse models. Some
studies state that dendritic cell cytokine secretion and stimulation of T cells is
only altered in lethal infections, while they function normally in nonlethal
infections, such as P. yoelii 17XNL and P. chabaudi AS [65]. Leisewitz et al.
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(2004) observed the response of the dendritic cell population to a P. chabaudi AS
infection and demonstrated that costimulatory markers on dendritic cells are
upregulated following infection [67]. Other research shows that Plasmodium
induces systemic maturation of dendritic cells, thereby altering their antigen
presentation capabilities and impairing the T cell response [66, 76]. Conversely,
other reports have shown that P. yoelii 17XNL infections inhibit dendritic cell
maturation and reduce the expression of costimulatory markers ([77, 78]). These
reports are similar to the findings presented here that a nonlethal strain of P.
yoelii does alters dendritic cell activation and proper T cell priming and
costimulation. However, one important caveat is our study looks at how DCs in
Plasmodium infected mice respond during subsequent infections, which has not
been addressed in prior studies.
When examining the costimulatory molecules on DCs, further evidence
was provided that stimulation of the T cells by the DCs is also impaired. These
findings are similar to other studies that have shown that DC activation and T cell
activation is compromised following a Plasmodium infection. Urban et al. (1999)
show that Plasmodium falciparum-infected erythrocytes affect the maturation of
dendritic cells and that activation markers on T cells are downregulated [63].
They also demonstrated that costimulatory molecules on DCs exposed to pRBCs
are downregulated. This study was the first to demonstrate that DCs could be
affected by pRBCs. Similarly, Millington et al. (2007) demonstrated that in a
Plasmodium infection, DCs are capable of eliciting a normal “signal 1” to T cells,
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or normal TCR engagement with the MHC I, but impair T cell clustering and
priming [69]. However, this study only analyzed CD40 on DCs and did not
examine any activation markers on the T cells themselves, therefore activation of
the T cells was not assessed.
Examining costimulatory molecules on dendritic cell populations provided
evidence that Plasmodium induced immunosuppression was not solely intrinsic
to T cell activation, but in dendritic cell activation as well. Expression of CD40,
CD80, and CD86, all costimulatory molecules, were downregulated 24 hours
following a Listeria infection (Figure 14). Curiously, the expression of CD40 and
CD80, but not CD86, was higher than that on DCs from naïve mice (Figure 14),
which suggests that DCs in Plasmodium infected mice were unable to further
upregulate expression of these costimulatory molecules following infection with
Listeria.
Although it has been shown that immunosuppression was induced during
DC activation, it is not clear what the causative agent is that is inducing
immunosuppression and altering the T cell response. Multiple studies have
attributed the suppressive effect of Plasmodium on DCs to hemozoin, the malaria
pigment [64, 68, 79-84]. When a Plasmodium parasite invades a red blood cell, it
digests hemoglobin, which in turn releases heme. Heme is toxic to the parasite,
thus it must convert heme into another compound, hemozoin, in order to promote
cell survival, thus promoting its own survival. Research shows that DCs that have
phagocytosed pRBCs containing hemozoin demonstrate immunosuppressive
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capabilities and diminished T cell activation along with a decrease in phagocytic
activity [64, 68]. Although that aspect was not examined in this study, hemozoin
is likely to have some effect on antigen presenting cells that have phagocytosed
pRBCs and may contribute to the alteration of the immune response to
secondary infections.
Upon T cell priming and activation, T cells will upregulate certain activation
markers. CD69 is the earliest detectable activation marker following TCR
engagement with the major histocompatibility complex (MHC). Following TCR
activation, CD69 is the first activation marker to be upregulated and expressed,
typically within 3 hours of stimulation [57, 58]. Effective T cell activation also
requires costimulation that involves the costimulatory molecules, CD80 and
CD86, expressed on the dendritic cell. These costimulatory molecules are
capable of ligating receptors CD28 and CTLA-4 on the T cell, however only CD28
ligation induces T cell activation. In contrast, CTLA-4 ligation downregulates the
immune response [57, 59]. CD25, another T cell activation marker, is expressed
following induction of CD69. CD25 expression is dependent on costimulatory
events and is only expressed following costimulation of T cells [59]. Alternatively,
other studies have shown that this marker is dependent on “signal 3” of T cell
priming, i.e., IL-12 stimulation [85]. Nevertheless, both of these signals occur
downstream of TCR engagement, thus T cell activation must be compromised
following TCR engagement as shown here by a reduction in CD25 and CD69
expression (Figure 13).
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It is also possible that T cell suppression is not due to a sole contributing
factor, but a network of components that impair T cell activation and dendritic cell
activity. Several studies have attributed LCMV’s suppressive capabilities to the
secretion of IL-10, an anti-inflammatory cytokine, by immunoregulatory antigen
presenting cells [86-89]. These studies demonstrate that dendritic cells specific
to LCMV secrete IL-10, thus downregulating the immune response and
perpetuating the viral infection [86-89]. Wilson et al. (2012) showed that during a
chronic LCMV infection immunoregulatory APCs (iAPCs) are expanded and
sustained, and they contribute to diminishing the antiviral T cell response [89].
These iAPCs were the major source of IL-10 during persistent viral infection and
simultaneously expressed multiple immunosuppressive molecules (PDL1, PDL2,
and IDO), while downregulating T cell stimulatory factors, such as IL-12.
Therefore, these cell types more than likely play a role in diminishing the antiviral
T cell response to prevent immunopathology during a persistent infection. On the
contrary, an acute infection induces the expansion of immunoregulatory APCs
but this population rapidly declines [89]. Although not examined in this study,
these observations suggest that Plasmodium may impair coinfection-specific T
cells through elevated production of IL-10 and immunoregulatory APCs. Further
investigation is needed in order to determine whether immunosuppression during
these two types of infections are similar or are occurring via distinct regulatory
pathways.
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It has been shown here that immunosuppression is not intrinsic to only
dendritic cells, but in the activation of T cells as well. Consequently, these
immunosuppressive events have been deemed responsible for the reduced
expansion of CD8 and CD4 T cells responding to a secondary infection. This
study has provided vital information that furthers the understanding of how
Plasmodium impairs host immune responses during heterologous infections.
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